Science news and articles on health, environment, global warming, stem cells, bird flu, autism, nanotechnology, dinosaurs, evolution -- the latest discoveries in astronomy, anthropology, biology, chemistry, climate & bioengineering, computers, engineering ; medicine, math, physics, psychology, technology, and more from the world's leading research centers universities.

Targeting 2 angiogenesis pathways could improve results of glioblastoma treatment

0

Two companion papers from Massachusetts General Hospital (MGH) research teams suggest that targeting multiple angiogenesis pathways simultaneously could help overcome the resistance to anti-angiogenic treatment inevitably developed by the devastating brain tumor glioblastoma. Appearing in PNAS Early Edition, the reports describe how two different methods of inhibiting both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in animal models not only normalized tumor blood vessels to a greater extent than anti-VEGF therapy alone but also shifted the action of tumor-infiltrating immune cells from a pro-tumor to an anti-tumor state.

"These papers offer a potential solution for glioblastoma's escape from anti-VEGF therapy, which is mediated by activating alternative growth factor pathways," says Rakesh K. Jain, PhD, director of the Steele Laboratory of Tumor Biology in the MGH Radiation Oncology Department and co-corresponding author of both papers. "In our back-to-back papers we not only provide proof-of-principle data that dual treatment strategies can slow glioblastoma growth and improve survival but also reveal the underlying mechanisms for these benefits."

The most common malignant tumor arising in the brain, glioblastoma is characterized by a highly abnormal, leaky and inefficient blood supply, caused by the overexpression of angiogenic factors like VEGF. These vascular abnormalities lead to swelling around the tumor and poor blood perfusion within the tumor, causing it to become more aggressive and resistant to chemotherapy and radiation treatment. While anti-VEGF treatment has become part of standard postsurgical treatment for glioblastoma, its beneficial effects are temporary and do not extend patient survival.

Previous studies from members of these MGH teams revealed that glioblastoma patients receiving anti-VEGF treatment also had a transient drop in blood levels of Ang-2. Levels of that factor rebounded as tumor progression resumed, suggesting that Ang-2 activity may contribute to resistance to anti-VEGF treatment. The researchers also found that, similar to VEGF, Ang-2 is expressed by all types of glioblastomas. To capture the diversity of different glioblastoma types, the investigators designed two methods of testing whether inhibiting both pathways could overcome treatment resistance.

One approach combined the use of the experimental oral anti-VEGF drug cediranib with an Ang-2-neutralizing antibody in two mouse models of glioblastoma and found that dual therapy improved blood vessel normalization and extended survival compared with cediranib treatment alone. Dual therapy also attracted tumor-associated macrophages (TAMs) to the tumors and increased the proportion of the anti-tumor form of those immune cells. Importantly, blocking the migration of TAMs to tumors reduced the benefits of dual therapy.

The second study used an antibody that targets both VEGF and Ang-2 and showed that dual treatment improved the architecture of tumor vessels in a mouse model with abnormal vessels. TAMs were reprogrammed to an anti-tumor state in both this tumor model and in another model not characterized by abnormal vasculature, indicating that vascular normalization was not the only mechanism of benefit. In fact, dual therapy promoted anti-tumor immunity by shifting the population of TAMs towards an anti-tumor form, consistent with the first study but regardless of whether or not surrounding blood vessels were abnormal.

"Our studies indicate that dual targeting of VEGF and Ang-2 could overcome some of the shortcomings of currently available glioblastoma therapies," says Jain, who is the Andrew Werk Cook Professor of Tumor Biology at Harvard Medical School. "Clinically accessible agents are currently available for this dual targeting strategy, and our finding that dual therapy can also improve anti-tumor immune responses, irrespective of its effect on blood vessels, is particularly timely given the rapid development of new immunotherapies. These results open new avenues of research on novel combinations to obtain more durable results against this devastating disease."

###

The co-lead authors of the study combining cediranib with an Ang-2 antibody are Teresa Peterson, Nathaniel Kirkpatrick and Yuhui Huang, all of the Steele Labs at MGH; and Dai Fukumura, MD, PhD, of the Steele Labs is co-corresponding author. Co-lead author of the study using the VEGF/Ang-2 antibody are Jonas Kloepper, Lars Riedemann, and Zohreh Amoozgar, of the Steele Labs; and Tracy Batchelor, MD, MGH Departments of Neurology and Radiation Oncology, is co-corresponding author. Support for the studies includes National Cancer Institute grants P01-CA080124 and P50-CA165962 and grants from MedImmune, Roche and the National Foundation for Cancer Research.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $800 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2015, MGH returned into the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Media Contact

Katie Marquedant
[email protected]
617-726-0337
@MassGeneralNews

http://www.mgh.harvard.edu

Leave A Reply

Your email address will not be published.